89346-82-7

Basic information

• Product Name: Tosylate of Tetraethylene glycol monobenzyl ether
• Synonyms: Tosylate of Tetraethylene glycol monobenzyl ether;2,5,8,11-Tetraoxatridecan-13-ol, 1-phenyl-, 4-methylbenzenesulfonate;1-phenyl-2,5,8,11-tetraoxatridecan-13-yl 4-methylbenzenesulfonate
• CAS NO: 89346-82-7
• Molecular Formula: C₂₂H₃₀O₇S
• Molecular Weight: 456.54968
• Mol File: 89346-82-7.mol
• Article Data: 25

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Tosylate of Tetraethylene glycol monobenzyl ether(CAS DataBase Reference)
• NIST Chemistry Reference: Tosylate of Tetraethylene glycol monobenzyl ether(89346-82-7)
• EPA Substance Registry System: Tosylate of Tetraethylene glycol monobenzyl ether(89346-82-7)

Safety Data

• Hazardous Substances Data: 89346-82-7(Hazardous Substances Data)

Usage

Uses

Benzyl-PEG4-Ots is a PEG-based PROTAC linker that can be used to synthesize PROTACs.

in vitro

PROTAC contains two distinct ligands linked by a linker; one is a ligand for the E3 ubiquitin ligase and the other is a ligand for the target protein. PROTAC utilizes the intracellular ubiquitin-proteasome system to selectively degrade target proteins.

Upstream product

• 86259-87-2 1-phenyl-2,5,8,11-tetraoxatridecan-13-ol 
• 112-60-7 Tetraethylene glycol 
• 100-39-0 benzyl bromide 
• 98-59-9 p-toluenesulfonyl chloride 
• 111-77-3 2-(2-methoxyethoxy)ethyl alcohol 
• 100-44-7 benzyl chloride 
• 4792-15-8 Pentaethylene glycol 

Downstream Products

• 129086-17-5 [2-(2-{2-[2-(2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-Pentadecafluoro-octyloxy)-ethoxy]-ethoxy}-ethoxy)-ethoxymethyl]-benzene 
• 129086-20-0 [2-(2-{2-[2-(2,2,3,3,4,4,5,5,6,6,7,7-Dodecafluoro-heptyloxy)-ethoxy]-ethoxy}-ethoxy)-ethoxymethyl]-benzene 
• 129086-13-1 [2-(2-{2-[2-(2,2,3,3,4,4,5,5,6,6,7,7,7-Tridecafluoro-heptyloxy)-ethoxy]-ethoxy}-ethoxy)-ethoxymethyl]-benzene 
• 129086-21-1 [2-(2-{2-[2-(2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-Hexadecafluoro-nonyloxy)-ethoxy]-ethoxy}-ethoxy)-ethoxymethyl]-benzene 
• 129086-22-2 [2-(2-{2-[2-(2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11-Icosafluoro-undecyloxy)-ethoxy]-ethoxy}-ethoxy)-ethoxymethyl]-benzene 
• 89346-83-8 2-<2-<2-<2-(benzyloxy)ethoxy>ethoxy>ethoxy>ethoxybenzene 
• 86770-76-5 2-(2-(2-(2-(benzyloxy)ethoxy)ethoxy)ethoxy)ethanamine 
• 134881-77-9 1,4-bis[2-(2-(2-(2-toluene-p-sulfonylethoxy)ethoxy)ethoxy)ethoxy]benzene 
• 134881-64-4 1,4-bis<2-<2-<2-<2-(4-benzyloxyphenoxy)ethoxy>ethoxy>ethoxy>ethoxy>benzene 
• 36366-93-5 2-<2-<2-(2-phenoxyethoxy)ethoxy>ethoxy>ethanol 
• 89346-76-9 2-<2-<2-(2-benzoyloxyethoxy)ethoxy>ethoxy>ethoxybenzene 
• 89346-85-0 2-<2-<2-<2-(aminobenzoyloxy)ethoxy>ethoxy>ethoxy>ethoxybenzene 
• 89346-84-9 2-<2-<2-<2-(nitrobenzoyloxy)ethoxy>ethoxy>ethoxy>ethoxybenzene 
• 89346-73-6 2-<2-<2-<2-<(diazonium tetrafluoroborate)benzoyloxy>ethoxy>ethoxy>ethoxy>ethoxybenzene 

Relevant articles and documents

TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT

The present invention relates to a target protein degradation-inducing Degraducer, a preparation method thereof, and a pharmaceutical composition for preventing or treating diseases related to EED, EZH2, or PRC2 comprising same as an active ingredient. A novel compound represented by formula 1, according to the present invention is a Degraducer compound that induces degradation of a target protein, i.e., embryonic ectoderm development (EED) or polycomb repressive complex 2 (PRC2), utilizing cereblon E3 ubiquitin ligase, von Hippel-Lindau tumor suppressor (VHL) E3 ubiquitin ligase, mouse double minute 2 homolog (MDM2) E3 ubiquitin ligase, and cellular inhibitor of apoptosis protein 1 (cIAP) E3 ubiquitin ligase, wherein the compound has an aspect of remarkably achieving target protein degradation-inducing activity through a ubiquitin proteasome system (UPS), and therefore there is a useful effect in that it is possible to provide a pharmaceutical composition for preventing or treating diseases or conditions related to a target protein, and a functional health food composition for preventing or improving same, comprising said compound as an active ingredient.

SMALL-MOLECULE INHIBITORS FOR THE Β-CATENIN/B-CELL LYMPHOMA 9 PROTEIN?PROTEIN INTERACTION

Disclosed are inhibitors for the β-catenin/B-cell lymphoma 9 interaction. The inhibitors are selective for β-catenin/B-cell lymphoma 9 over β-catenin/ E-cadherin PPI interaction. Methods of using the disclosed compounds to treat cancer are also disclosed.

Optimization of IEDDA bioorthogonal system: Efficient process to improve trans-cyclooctene/tetrazine interaction

The antibody pretargeting approach for radioimmunotherapy (RIT) using inverse electron demand Diels-Alder cycloaddition (IEDDA) constitutes an emerging theranostic approach for solid cancers. However, IEDDA pretargeting has not reached clinical trial. The major limitation of the IEDDA strategy depends largely on trans-cyclooctene (TCO) stability. Indeed, TCO may isomerize into the more stable but unreactive cis-cyclooctene (CCO), leading to a drastic decrease of IEDDA efficiency. We have thus developed both efficient and reproducible synthetic pathways and analytical follow up for (PEGylated) TCO derivatives, providing high TCO isomeric purity for antibody modification. We have set up an original process to limit the isomerization of TCO to CCO before the mAbs’ functionalization to allow high TCO/tetrazine cycloaddition.